URGENT/CRITICAL NEED for ALL DONATIONS & BLOOD TYPES especially Type O and Platelets. Click here to schedule your donation and help spread the word!

There is no deferral for COVID-19 vaccinations currently being administered in the U.S. and donors are not required to show status. Learn more about our Coronavirus Pandemic Response and COVID-19 Vaccinations. Face masks and appointments are required. Appointments can be made the day of donation by contacting us at 800-747-5401.  

We're excited to announce that our organization is now officially named ImpactLife! Read more about our evolution here: www.bloodcenter.org/impactlife 

Therapeutic apheresis services are a consultative service provided to hospitals under a contractual agreement. ImpactLife is licensed by the US Food and Drug Administration and accredited by AABB.

ImpactLife's Patient Services team of physicians and specialty trained nurses provides safe, effective care throughout the procedure. Support is available 24 hours a day, seven days a week.

ImpactLife provides training to hospital staff on the process, requirements, and documentation related to the procedures. CE credits are available.


WHEN IS Therapeutic apheresis USED?

Therapeutic apheresis is effective in treating the symptoms of a number of diseases where the plasma contains a known pathologic component. By removing the symptom-causing substances from the plasma, patients experience symptom relief.

Ideally, the plasma exchange procedure will remove these substances faster than the body can make them. For example, in some autoimmune disorders, therapeutic apheresis is used to remove the existing harmful antibodies while drugs suppress their future production.

There are numerous indications for TA. Indications have been categorized by the American Society for Apheresis (ASFA) and AABB after review of published studies based on outcome data.

We recommend that the technique be limited to situations of expected major benefit. Less established uses of therapeutic apheresis are considered upon consultation and discussion with an ImpactLife physician.

Established Indications for Therapeutic Apheresis

PLASMA EXCHANGE

  • Chronic Inflammatory Demyelinating Polyneuropathy
  • Hyperviscosity Syndrome
  • Thrombotic Thromboctyopenic Purpura
  • Lambert-Eaton Myasthenic Syndrome
  • Multiple Myeloma
  • Waldenström's Macroglobulinemia
  • Goodpasture's Syndrome (Anti-GBM disease)
  • Myasthenia Gravis
  • Kidney Transplant Rejection
  • Guillain-Barré Syndrome
  • Post-transfusion Purpura
  • Drug Overdose of Protein Bound Drugs


CELL DEPLETION

  • Leukocytosis with Leukostasis
  • Severe Thrombocytosis with Compromised Circulation


RED CELL EXCHANGE

  • Sickle Cell Anemia
  • Malaria or Babesiosis

ORDERING THERAPEUTIC APHERESIS

To request a therapeutic apheresis procedure, call 563-349-1677 and provide the following information:

  • Diagnosis
  • Symptoms
  • Date of birth, weight, height
  • Start date & frequency of treatment
  • Current medications
  • Pertinent lab and imaging results supporting the treatment indication, as well as CBC, BCP
  • Ordering physician email and phone number
  • Other medical conditions (e.g. heart disease, kidney disease)
  • Vascular access to be used 
  • Patient demographic information & location of treatment

Once patient needs and urgency have been determined and the procedure has been scheduled, the ImpactLife team will be dispatched to the hospital.

The patient is closely monitored throughout the procedure for adverse effects and a clinical record is left with nurse/physician. In the event of a change in clinical status, the patient's nurse and/or physician is immediately notified for collaborative care.

VASCULAR ACCESS

No procedures can be scheduled without understanding what venous access will be available. Peripheral access must be equivalent to bilateral 17 gauge thin-walled IV access to allow acceptable flow rates. Patients who do not have adequate peripheral access should have a Quinton-type dual lumen central line. PICC lines and Groshong catheters are not appropriate for use with therapeutic apheresis procedures. Central access will generally need to be sufficient to support flows similar to those required for hemodialysis. ImpactLife will ask that your patient's access is capable to handle the procedure and if not, to ensure access prior to ImpactLife arriving for the procedure.